



# Annual report 2022



## ABOUT ECL

The [Association of European Cancer Leagues \(ECL\)](#) is one of the most prominent non-profit organisations active in health policy at the European level. Independent of commercial influence, ECL unites, supports and represents cancer leagues across the WHO European region. Established in 1980 by prominent NGOs and experts, ECL is based in Brussels (Belgium).

The [vision](#) of ECL is for a Europe Free of Cancer. ECL's [mission](#) is to influence and improve cancer control and cancer care in Europe. This is done by providing a forum and voice for experienced cancer societies and supporting new entrants facilitating collaboration and knowledge sharing, primarily in the areas of cancer prevention, access to medicines and patient support, as well as creating opportunities to advocate for these issues at the EU level.

Since its creation, ECL has grown in achievements and leadership, earning an international reputation for being an independent and impactful voice in cancer control. ECL's eminent status in Europe today is due to the successful collaboration with its members on the ground, other NGOs, research institutes and global and European institutions, including the WHO's International Agency for Research on Cancer (IARC), the European Commission and the European Parliament.

**[www.cancer.eu](http://www.cancer.eu)**



# MESSAGE FROM THE PRESIDENT and EXECUTIVE DIRECTOR



## A Year of Impact and Progress

We are proud to see ECL stronger and more active than before, in our 42<sup>nd</sup> year. We are where we are because of the amazing members who make up the ECL network.

This is a very different organisation than the one created in 1980. We have grown in achievements and impact not only at the national level among the leagues, but also by leaps and bounds at the European umbrella level.

Cancer leagues remain the main resource for the public for cancer control information and services. In many countries, they are also an important source of funding for research.

In adherence to our current strategic goals, we continued our relentless pursuit of influencing European cancer control policies, promoting prevention, enhancing access to screening and early diagnosis, ensuring equal access to high-value treatments, and developing robust support structures for cancer patients, survivors, and caregivers.

Our continued engagements with our esteemed members on the ground and umbrella European partners have fostered impactful collaborations, allowing us to contribute significantly to the international dialogue on cancer control, prevention, and patient support.



Financially, we are grateful for the continuous support from our members and from the European Commission, which makes it possible for us to maintain our independence from commercial interests.

We are also pleased to see that Europe's Beating Cancer Plan is well under way, and are committed to continue to support in its implementation. One way we are doing this is by being involved in more EU-funded projects that are committed to making the elements a reality. The BUMPER project which we are leading, for example, aims to raise the awareness of cancer prevention among the general public, in particular the European Code Against Cancer.

We have enlarged our team at the Secretariat to better support our working groups and task force, nurture the Youth Ambassadors program, and fostering themed activities which have been pivotal in building organizational capacity and empowering the next generation of cancer advocates.

As we look forward, our commitment to a Europe Free of Cancer remains resolute. The challenges ahead are met with optimism, knowing that our collective efforts will continue to drive positive change.

**Professor Rui Medeiros**  
ECL President

**Dr Wendy Yared**  
ECL Executive Director



# ECL EXECUTIVE BOARD

ECL is governed by an Executive Board of Directors.

The Executive Board is responsible for ECL's strategy, directions and main activities, organisational development, communications and relationship with members and other relevant organisations.

Board members are volunteers and do not receive remuneration for their roles. Our Board of Directors consists of representatives of our members. The Board of Directors is elected via the General Assembly of member leagues.

ECL is grateful for their support, dedication, and active contributions to the work of ECL throughout the years, as well as for their valuable advice in guiding the ECL Secretariat in its activities.

The 2022 Executive Board comprised of the following six members:



**Rui Medeiros**, President,  
*Portuguese League against  
Cancer*



**Nicolas Philippou**, Vice-  
President, *Cyprus Association  
of Cancer Patients and Friends*



**Lucienne Thommes**,  
Treasurer, *Foundation Cancer  
Luxembourg*



**Darina Sedláková**, *League  
Against Cancer Slovakia*



**Ana  
Fernández Marcos**, Spanish  
Association Against Cancer



**Jesper Fisker**, Danish Cancer  
Society



# ECL SECRETARIAT

The ECL Secretariat based in Brussels is managed by the Executive Director and her team.

ECL's activities are planned and implemented in line with ECL's vision and mission, the ECL Strategy 2019-2023, and the commitments taken under the Operating Grant and other EU-funded projects for 2022.

ECL is a fully compliant member of the EU Transparency Register (Number 19265592757-25).

## ECL Secretariat staff

The core team at the ECL Secretariat in Brussels in 2022:

- Wendy Yared, Executive Director
- David Ritchie, Cancer Prevention Manager
- Ginevra Papi, Communications & Public Relations Officer
- Toma Mikalauskaitė, Senior Policy Officer for Access to Medicines & Advocacy Coordination, from October 2022
- Sara Bertucci, Policy Officer for Cancer Prevention & Survivorship, September 2022
- Helena Ros Comesaña, EU Research Projects Officer, from 5 September 2022
- Flore Rennesson, Junior Policy Officer, to September 2022
- Linda Abdelall, Policy & Projects Officer, to 31 March 2022

Additionally, the Secretariat had part-time and short-term support in 2022:

- Florence Boivin, Office Manager Contractor, at 30%
- Tanja Gohlert, Operations & Finance Officer Contractor at 50%, from November
- Meritxell Mallafré-Larrosa, Research Associate, Freelance
- Sabrina Amichetti, Digital Communications Associate, Freelance, from April 2022
- Thomas Tharakan, Operations & Finance Officer Contractor, at 20%, to October 2022
- Francesca Malegiannakis, Communications & Community Assistant at 100%, to June 2022
- Anamaria Szabo, Communications & Community Assistant at 100%, to February 2022





# ECL Strategic Goals 2019-23

ECL's Strategy developed originally for 2019 to 2021, was extended to 2023 by the Executive Board in order to devote time and resources for an evaluation exercise leading to a new strategy to be adopted by the General Assembly in 2023.

ECL's activities continued to follow its approved Strategy of 2019, which was found to still be in line with ECL's values and mission, as well as with EU cancer control priorities:

## **Goal 1 Influence cancer control policies**

Maintain and strengthen ECL's position in influencing European cancer control policies. Work for and support the development and implementation of national cancer control programmes, this includes European collaboration, establishment and support to cancer registries, epidemiological, clinical and basic cancer research in all European countries.

## **Goal 2 Promote cancer prevention**

Promote the evidence-based knowledge to prevent cancer, such as messages of the European Code Against Cancer in order to reduce cancer incidence and mortality in Europe. Advocate for the implementation of governmental policies and actions supporting messages of the European Code Against Cancer.

## **Goal 3 Enhance access to cancer screening and early diagnosis**

Enhance access to scientifically proven effective and quality-controlled cancer screening programmes in accordance with EU guidelines and relevant international evidence. Support early detection of cancer.

## **Goal 4 Ensure equal access to high value cancer treatments for all cancer patients in Europe**

Advocate for equal access to effective cancer treatments and therapies for all European patients by insisting on accessibility, sustainability of the healthcare system and transparency of medicines prices.

## **Goal 5 Develop actions supporting cancer patients, survivors and caregivers**



Improve support services and ensure access to high quality treatment interventions and care for all cancer patients, survivors and caregivers in Europe. Promote the rights and address inequalities throughout the whole patient pathway.

## **Goal 6 Grow membership and increase impact of ECL in Europe**

Actively contribute to the growth of the organisations by promoting ECL's work in Europe. Boost the impact of ECL by strengthening its voice in cancer control advocacy. Ensure membership of relevant cancer societies in ECL.





# ECL Secretariat Activities

## Convening

We regularly convene our members, partners, collaborators and interested stakeholders for discussion and exchange, building consensus and co-ordinating activities, including through events and campaigns.

We invest in collaboration, bringing together those who share our mission and vision to promote multidisciplinary for the benefit of patients, as well as advocating for better cancer control policies in Europe and beyond.

### Events

ECL was active in varying capacities, as (co-)organisers, speakers, dissemination partners or active participants in more than 280 webinars, conferences, meetings, workshops and events in 2022. These included events organized in our roles in EU-funded projects.

ECL responded regularly to requests for information and data for briefings, speeches and presentations from our member leagues, Members of the European Parliament, European Commission civil servants, health-focused civil society organisations and journalists.

### Networking

ECL met and exchanged information regularly throughout the year with various cancer and/or umbrella and national health-focused organisations and institutions, as well as major conference organisers such as the Economist, to strengthen collaboration and avoid duplication of efforts. In 2022, we collaborated in varying degrees with the World Health Organization (WHO), with WHO's International Agency for Research on Cancer (IARC), Smoke Free Partnership (SFP), the European Public Health Association (EPHA), Health and Environment Alliance (HEAL), European Cancer Patient Organisation (ECPC), the European Society for Paediatric Oncology (SIOPE), European Oncology Nursing Society (EONS), European Society for Medical Oncology (ESMO), the Union for International Cancer Control (UICC), the European Alcohol Policy Alliance (EUROCARE) and many others!

## Capacity building

We are the voice of cancer leagues, amplifying the important work of our members at the national and regional level. On behalf of member leagues, we coordinate various activities, including those of our official working groups and task force.

Led by chairs, vice-chairs and subgroup leaders from our member leagues, the working groups and task force have been established to facilitate consensus and joint projects around



3 key thematic areas: cancer prevention & early detection, access to medicines and patient support.

## Patient Support Working Group (PSWG)



Established in 2007, the PSWG is the longest-running of ECL's working groups. PSWG members are cancer care experts working for cancer leagues across Europe who share best practices, develop guidelines and other resources to raise awareness of issues affecting patients, survivors, caregivers, and others, as well as advocate to improve quality of care at the national and European level.

The ECL Secretariat coordinates the ECL Patient Support Working Group (PSWG), chaired by Monick Leal from the Portuguese League Against Cancer (since November 2021).

In 2022, the PSWG collaborated on 3 subgroup areas:

- 1/ Sexuality & Cancer
- 2/ Cancer & Work
- 3/ Cancer Rehabilitation

Members of the PSWG have worked together in generating a number of valuable publications to support cancer patients, carers, health care professionals and even employers:  
<https://www.cancer.eu/other-focus-pswg-publications/>

## Access to Medicines Task Force (A2M TF)



Since 2016, the ECL Secretariat with this A2M Task Force has been connecting public affairs, advocacy, and research colleagues from cancer leagues with the aim of ensuring that safe and effective medicines are available to all cancer patients in Europe. The Task Force advocates for accessibility, availability, affordability and increased transparency related to the prices of medicines, which are needed for sustainable healthcare systems.



The ECL Access to Medicines Task Force (A2M TF) in 2022 was chaired by Ward Rommel of Stand up to Cancer Flanders (since September 2019) and supported by the Steering Committee, made up of Amandine Courtin (French League Against Cancer), Dimitri Kohler (Swiss Cancer League), Guy Muller (Dutch Cancer Society), and Maria Krini (PASYKAF of Cyprus).

In 2022, it had four thematic areas:

- 1/ R&D models and Fair Pricing
- 2/ Cross-border collaboration and joint procurement
- 3/ Orphan and Paediatric Medicines
- 4/ Medicines shortages

The Task Force has collaborated on a number of rich advocacy documents:  
<https://www.cancer.eu/a2madvocacy/>

### **A2M TF and the European Fair Pricing Network (EFPN)**

The EFPN is hosted by ECL's member, the Dutch Cancer Society, represented by Guy Muller. This network works with partner cancer societies and the Netherlands Cancer Institute (NKI) to provide research to guide actions on making cancer medicine prices fairer, while upkeeping the innovation pipeline and early access for patients to promising new medicines. ECL collaborates with EFPN by participating in their Steering Committee meetings, keeping regular communications, and seeking opportunities for advocacy and dissemination activities.

### **Prevention & Early Detection Working Group (P&ED WG)**



The Prevention and Early Detection Working Group is ECL's youngest working group. It was created in June 2020, following a consensus statement produced in 2019. The P&ED WG connects health promotion, research and communication specialists from member leagues. Subgroups were created in 2021 as a response to priority areas at the national and European level. Members agreed to work in the subgroup areas of 1/ Early Detection, 2/ Tobacco Control, and 3/ obesity. Work in the P&ED WG are always evidence-based, such as those provided for the WHO IARC's European Code Against Cancer.



The ECL Secretariat coordinates the ECL Cancer Prevention and Early Detection Working Group (P&ED WG), currently chaired by Cristiana Fonseca of the Portuguese League against Cancer and co-chaired by ECL Executive Board Member Darina Sedláková (since November 2020).

## ECL Youth Ambassadors for the European Code Against Cancer (ECL YAs)

Since 2015, the ECL Secretariat has been supporting, training and empowering the ECL Youth Ambassadors (ECL YAs) for the dissemination of the European Code Against Cancer (ECAC). The ECL YAs programme is a decentralised network of students and young professionals from different backgrounds, countries and ages who share a deep conviction that cancer can be defeated by following the 12 messages of the ECAC.



In 2022, the YA programme was made up of 57 Youth Ambassadors from across 35 countries in the WHO European region. ECL secretariat co-ordinated and supported ECL YAs to organise a variety of individual and joint activities, projects, campaigns and events. Some highlights from activities by the YAs in 2022 included: an intervention by Bosnian YA at the French Presidency's high-level conference on Horizon Europe (HE)'s Cancer Mission & Citizen Engagement; by a Greek YA selected to be part of HE's Cancer Mission, by an Armenian YA invited to attend and speak at WHO/Europe's Tirana Health and Well-being Forum for Youth; and by a Bulgarian YA who was interviewed by national radio station.

## Advocacy

On behalf of our members, we have proven to be a leading organisation in influencing cancer policy and advocating at the European level, as well as a useful resource to European institutions to convene and facilitate across countries and professions.

We advocate on key policy issues, speaking with one voice on behalf of cancer leagues, to enhance the impact of their expertise and experience.

## MEPs Against Cancer (MAC) Interest Group



ECL provides the Secretariat for the European Parliament's MEPs Against Cancer (MAC) interest group, which entails (i) organising multi-stakeholder policy dialogues and events with MEPs and (ii) sharing policy papers and recommendations.

MAC is the largest and oldest informal cross-party network established in 2005 by MEPs for MEPs, to work on cancer policy at the European Parliament. Since 2021, the membership counted 128 MAC MEPs from 24 Member States, from all 7 EU political groups represented, including non-attached.

## EU initiatives, joint actions & projects



**Co-funded by  
the European Union**

ECL continued to be active on a number of EU-funded projects, which are all linked to ECL's Strategic Goals and members' interests.

**CBIG-Screen (2021 to 2026)**



Goal: To tackle inequality in cervical cancer screening (CCS) continuum, particularly regarding access to screening by vulnerable populations.

Coordinated by the Institut National de la Santé et de la Recherche Médicale (INSERM), the project aims to create a Europe-wide knowledge framework around barriers to cervical cancer



screening and generate policies, programmes and communications services to meet the needs of underserved sub-populations of women with inherent high-risk of cervical cancer and low access to proper healthcare routes.

ECL leads in the communication and dissemination work package and is the deputy leader of the Work Package 2 on stakeholder engagement.

### PAINLESS (2022 – 2027)



Goal: To adapt and implement a cost-effective, home-based intervention based on neuromodulation to reduce pain and improve quality of life of cancer patients with chronic pain.

Coordinated by the University of Santiago de Compostela (USC), the project focuses on a home-based neuromodulation treatment, based on the knowledge of the central mechanisms involved in cancer pain.

ECL participates in Work Package 6 on Communication and dissemination to identify and contact relevant stakeholders.

### CanScreen-ECIS (2022 – 2024)



Goal: To update the existing European Cancer Information System (ECIS) and improve the quality and coverage of cancer screening programmes in Europe.

Coordinated by WHO's International Agency for Research on Cancer (IARC), the project aims to integrate performance data from cancer screening programmes in European countries to the existing ECIS with an ultimate objective of empowering the programmes to evaluate their own performance on a continued basis and improve quality. In doing so, the project will refine performance indicators to better compare performance across different settings.



ECL co-leads with IARC in WP1 (Project Management & Coordination), with with ScienSano in WP6 (Engagement with EU Member States) and contributes to WP3 (developing a sensitization workshop on quality assurance interventions).

## BUMPER (2022 - 2024)



Goal: Implementation of the European Code Against Cancer (ECAC) messages, with special attention towards addressing health literacy to better connect with marginalized and vulnerable groups.

ECL is the coordinator of this project which supports and enhances the design, development and targeted promotion of the so-called 'EU Mobile App for Cancer Prevention' – a flagship initiative of Europe's Beating Cancer Plan – in order to prepare for the widespread dissemination of the App amongst the general population through training, piloting and promotion. The App will be a key tool in the promotion of the European Code Against Cancer (ECAC), including the most updated version of evidence produced within the ECAC's update (5th edition). The App will be developed specifically to broaden and extend the coverage of the ECAC.





## SELECTED HIGHLIGHTS OF 2022

### European Week Against Cancer (EWAC), 25-31 May 2022



EUROPEAN WEEK AGAINST CANCER  
25-31 MAY 2022

ECL has been coordinating the European Week Against Cancer (EWAC) since 2010, as part of a commitment to the first EU Joint Action against cancer EPAAC (European Partnership Against Cancer), where ECL led on the work package on Cancer Prevention and Health Promotion.

EWAC takes place the last 7 days of each year, to conclude the week with World No Tobacco Day on 31 May.



In 2022, ECL's EWAC campaign highlighted and focused on the role that each one of us has in accelerating the implementation of Europe's Beating Cancer Plan (#EUCancerPlan) – a core priority of the European Commission in the 2019-2024 legislative term.

During #EWAC22, ECL raised awareness about the initiatives and actions outlined in the Implementation Roadmap of Europe's Beating Cancer Plan, as well as promote cancer leagues' recommendations for European and national decision-makers.





# ECL ACTIVITIES

**EWAC**  
European Week  
Against Cancer

25-31 May

ECL has been coordinating EWAC since 2010. EWAC was revitalised to capitalise on proven strategies for communicating the European Code Against Cancer and has, since then, been a way to raise awareness and bring together the cancer community to call for EU action.

## • HEAL-ECL Materials



## Newsletter

2052 subscribers reached

## Social media

15 tweets  
8212 accounts reached

8 LinkedIn posts  
4023 views

10 Facebook posts  
1578 accounts reached

## • Events

**ECL webinar**  
**Breastfeeding & Hormone Replacement Therapy**  
25 May 2022  
14:00-15:15 CEST

**Register now!**

**12**

webinar on breastfeeding  
HRT & the European Code  
against Cancer (ECAC) - 25  
May

116 total clicks on the  
registration link  
111 views on YouTube

**ECL Webinar**  
**Let's break down the barriers around cancer and work!**  
30 May 2022  
13:00-15:00 CEST

**EURO CARRERS**

Policy dialogue on cancer  
at work - 30 May

284 total clicks on the  
registration link  
66 views on YouTube





## ECL 42nd Annual Meetings, 14-15 November 2022



ECL's 42nd Annual meetings took place in Limassol, Cyprus, hosted by the Cyprus Anti-Cancer Society as it celebrated its 50<sup>th</sup> anniversary in 2022.

The theme of the 2022 Annual Conference was on Equity, Quality, and Innovation in Cancer Care.



The keynote was provided by none other than [Stella Kyriakides](#), the EU Commissioner for Health and Food Safety, who praised the important and essential work and services provided by cancer leagues to the European populations.





Sessions at the 2022 Annual Conference were on 1/ Comprehensive Cancer Care, 2/ Inequalities, Inequity, and Disparities in Cancer Care, 3/ Precision Medicine and 4/ Gaps and Challenges in Survivorship and Supportive Care.



The Annual Conference was followed by the **Annual General Assembly**, the annual business meeting of the Association attended by CEOs and senior managers.





# ECL MEMBERS

ECL is committed to growing and nurturing a strong network of members and partners, fostering knowledge-sharing and empowering cancer leagues.

ECL exists for and because of our members, and the amazing work they do to fight cancer on all fronts is what drives us to keep trying to support their needs and influence policy on their behalf. We are proud to represent cancer leagues at the EU level and we will keep working hard to make beating cancer a mission possible.

ECL members are cancer societies operating across the whole cancer continuum and patient pathway - from cancer research and awareness to patient support during and after diagnosis. Cancer leagues are the main resource for the public for cancer control information and services.

From Iceland to Cyprus and Turkey, cancer leagues contribute to preventing and fighting cancer by, amongst other things, raising awareness and educating people about cancer, investing in research and providing support to cancer patients and their families during and after treatment.

In 2022, our member leagues together employed more than 8,000 staff and 1,100,000 volunteers, and represented more than 570,000,000 citizens. They raised and spent over €700,000,000 for cancer research.

ECL has a total of 31 members from 26 countries in the WHO European Region, covering 21 EU member states.







## **ECL MEMBERS 2022**

Foundation Against Cancer Belgium  
Foundation Against Cancer  
Stand Up To Cancer Flanders  
Croatian League Against Cancer  
Cyprus Anti-Cancer Society  
Cyprus Association of Cancer Patients and Friends  
League Against Cancer Prague  
Danish Cancer Society  
The Faroe Islands' Cancer Society  
Cancer Society of Finland  
French League Against Cancer  
German Cancer Society  
Hungarian League Against Cancer  
Icelandic Cancer Society  
Irish Cancer Society  
Israel Cancer Association  
Italian League Against Tumours  
Cancer Foundation Luxembourg  
Emanuele Cancer Research Foundation Malta  
Dutch Cancer Society  
Polish Cancer League  
Portuguese League Against Cancer  
Romanian Cancer Society  
League Against Cancer Slovakia  
Association of Slovenian Cancer Societies  
Spanish Association Against Cancer  
Catalan Federation Against Cancer



Swiss Cancer League

Turkish Association for Cancer Research & Control

Cancer Focus Northern Ireland

Cancer Research UK



# ECL FINANCIALS

## AUDITOR'S REPORT FOR 2022



Bedrijfsrevisoren  
Réviseurs d'Entreprises  
Registered Auditors  
Betriebsrevisoren

Kortemansstraat 2a • B-1731 Zellik

☎ +32 2 801 13 89

ASSOCIATION OF EUROPEAN CANCER  
LEAGUES ASBL  
Chaussée de Louvain 479  
1030 Brussels

### AUDITOR'S REPORT FOR THE FINANCIAL YEAR STARTED ON THE 1<sup>ST</sup> OF JANUARY 2022 AND ENDED ON THE 31<sup>ST</sup> OF DECEMBER 2022 OF THE ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) – RPR 0867.170.595

#### *Objective and scope of the review*

In accordance with our assignment defined below and confirmed by the Engagement letter of the 16<sup>th</sup> of March 2023, we report to you on the audit of the financial statements for the year ended the 31<sup>st</sup> of December 2022. The intended users are the members of the Board of Directors.

We have audited the financial statements of the ASSOCIATION OF EUROPEAN CANCER LEAGUES ASBL (ECL) for the year that ended on the 31<sup>st</sup> of December 2022, prepared in accordance with the accounting legislation applicable in Belgium, which show a balance sheet total of € 962.302,79 and a profit for the year of € 63.859,97.

The Board of Directors of the ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) ASBL is responsible for the preparation of financial statements that give a true and fair view in accordance with the accounting legislation applicable in Belgium, and for implementing the internal control that the Board of Directors believes is necessary to draw up financial statements that do not contain any significant anomalies.

In accordance with our Engagement Letter, our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the standard relating to the contractual audit of SME's and small (international) not-for-profit associations and foundations and the shared legally reserved tasks in SME's and small (international) not-for-profit associations and foundations.

This standard requires that we plan and perform the audit to ensure that the financial statements are free from material misstatement. We have complied with all deontological requirements relevant to the contractual audit of the financial statements in Belgium, including those related to independence as provided for in the aforementioned standard.

Our audit includes activities as provided for in the standard with regard to the contractual audit of SMEs and small (international) non-profit organizations and foundations and the shared legally reserved tasks in SMEs and small (international) non-profit organizations and foundations in order to obtain audit information about the amounts and notes included in the financial statements.

The selected activities depend on the professional judgement of the auditor, including a limited assessment of the risks of a material misstatement of the financial statements. We have designed audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) ASBL internal control.



Registered Auditors

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion, in accordance with the provisions of the standard concerning the contractual audit of SMEs and small (international) non-profit organizations and foundations and the shared legally reserved tasks of SMEs and small (international) non-profit organizations and, the attached financial statements give a true and fair view of the assets and financial situation of the ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) ASBL as of the 31<sup>st</sup> December 2022, and of its results for the financial year then ended, in accordance with the accounting legislation applicable in Belgium.

This report is not suitable for other purposes and its distribution is limited to the intended use as provided in the Engagement letter

Zellik, 28 March 2023

---

**L&S Registered Auditors**  
represented by  
**Saskia Luteijn**  
Partner



**European Cancer Leagues ASBL**  
**Chaussée de Louvain 479**  
**1030 Brussels**

**BALANCE SHEET AS AT DECEMBER 31, 2022**

**ASSETS**

**FIXED ASSET**

Website	8.396,70	
Depreciation	-8.396,70	
Furniture	12.260,62	
Depreciation	<u>-6.520,39</u>	
		5.740,23

**AMOUNTS RECEIVABLE WITHIN ONE YEAR**

Receivables	66.922,00	
Other receivables	<u>0,00</u>	
		66.922,00

**CASH AT BANK AND IN HAND**

BNP Paribas Fortis Bank	806.772,09	
Business depo	0,00	
Petty cash	<u>30,98</u>	
		806.803,07

**DEFERRED CHARGES AND ACCRUED INCOME**

Deferred expenses	4.348,16	
Accrued revenues	<u>78.489,33</u>	
		<u>82.837,49</u>

<b>TOTAL ASSETS</b>		<b>962.302,79</b>
---------------------	--	-------------------



## P&L ACCOUNT AS OF DECEMBER 31,2022

### OPERATING INCOME AND CHARGES

Turnover : Membership fees	221.992,00
Unrestricted Grant / Donation	60.000,00
Grant EC	757.991,33
Other income	-56.487,63
Total income	<b>983.495,70</b>
Services and other goods	-554.125,43
Remuneration and social security costs	-361.810,18
Depreciation and write-off on receivables	-2.575,44
Operating profit	<b>64.984,65</b>

### FINANCIAL INCOME AND CHARGES

Financial income	283,97
Financial charges	-1.408,65
Current profit of the year	<b>63.859,97</b>

### OTHER INCOMES AND CHARGES

Other incomes	0,00
Other charges	0,00
Withholding tax on financial income	0,00

<b>REVENUES IN EXCESS OF EXPENSES</b>	<b>63.859,97</b>
---------------------------------------	------------------





## ECL's Income Sources 2022

In 2022, ECL's total P&L Income was EUR 983,495.70.

The operational budget is devoted to our core operational and project activities to improve cancer control and care and strengthen the voice of national and regional cancer leagues across Europe.


Our biggest financial contributor is the European Commission. Co-financing was in the form of an Operating Grant and funding for other EU Projects. In 2022, contribution from the Commission represented 73% of ECL's total Operating Income.

In 2022, the total contribution from membership fees represented 21% of the Operating Income.


An unrestricted educational grant from Garnier International represented the remainder of our income, representing 6% of the total income.

ECL accepts industry contributions only in the form of unrestricted educational grants, and on the condition that companies cannot influence how the funding is used by ECL. Importantly, corporate contributions are never applied to core operating costs.

ECL INCOME SOURCES 2022



■ MEMBERSHIP FEES  
■ EUROPEAN COMMISSION OPERATING GRANT AND OTHER PROJECTS  
■ UNRESTRICTED GRANT / DONATION



■ NON-INDUSTRY ■ INDUSTRY



[www.cancer.eu](http://www.cancer.eu)



@CancerLeagues



@CancerLeagues



[ecl@cancer.eu](mailto:ecl@cancer.eu) | +32 256 2000



chaussée de Louvain 479, 1030 Brussels, Belgium

*proud to be*



Co-funded by  
the European Union